Tiotropium / Respimat One Year Study in COPD.

Completed · Phase 3 · Has a placebo group

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.

Key facts

Study ID

NCT00387088

Run by

Boehringer Ingelheim

People needed

3991

Starts

2006-09-01

Last updated by the study team

2014-05-16

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female
• At least 40 years old
• Smoker or ex-smoker
• Smoking history > 10 pack-years
• Forced Expiratory Volume in 1 Second (FEV1) < 60% predicted

You may not qualify if…

• Recent history of myocardial infarction, life-threatening cardiac arrhythmia or hospitalisation for cardiac failure
• History of asthma or allergic conditions.
• Malignancy requiring treatment within past 5 years
• Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis
• Known active tuberculosis
• Known hypersensitivity to anticholinergic drugs.

Where it is running

• 205.372.01020 Boehringer Ingelheim Investigational Site — Birmingham, Alabama, United States
• 205.372.01062 Boehringer Ingelheim Investigational Site — Mobile, Alabama, United States
• 205.372.01048 Boehringer Ingelheim Investigational Site — Berkeley, California, United States
• 205.372.01037 Boehringer Ingelheim Investigational Site — Huntington Park, California, United States
• 205.372.01058 Boehringer Ingelheim Investigational Site — Long Beach, California, United States
• 205.372.01059 Boehringer Ingelheim Investigational Site — Long Beach, California, United States
• 205.372.01007 Boehringer Ingelheim Investigational Site — Los Angeles, California, United States
• 205.372.01034 Boehringer Ingelheim Investigational Site — Los Angeles, California, United States
• 205.372.01028 Boehringer Ingelheim Investigational Site — Rancho Mirage, California, United States
• 205.372.01011 Boehringer Ingelheim Investigational Site — San Diego, California, United States
• 205.372.01066 Boehringer Ingelheim Investigational Site — Boulder, Colorado, United States
• 205.372.01008 Boehringer Ingelheim Investigational Site — Norwalk, Connecticut, United States
• 205.372.01004 Boehringer Ingelheim Investigational Site — Brandon, Florida, United States
• 205.372.01060 Boehringer Ingelheim Investigational Site — Clearwater, Florida, United States
• 205.372.01069 Boehringer Ingelheim Investigational Site — Miami Beach, Florida, United States
• 205.372.01023 Boehringer Ingelheim Investigational Site — West Palm Beach, Florida, United States
• 205.372.01053 Boehringer Ingelheim Investigational Site — Winter Park, Florida, United States
• 205.372.01045 Boehringer Ingelheim Investigational Site — Calhoun, Georgia, United States
• 205.372.01043 Boehringer Ingelheim Investigational Site — Normal, Illinois, United States
• 205.372.01061 Boehringer Ingelheim Investigational Site — Dubuque, Iowa, United States
• 205.372.01035 Boehringer Ingelheim Investigational Site — Wichita, Kansas, United States
• 205.372.01049 Boehringer Ingelheim Investigational Site — Shreveport, Louisiana, United States
• 205.372.01015 Boehringer Ingelheim Investigational Site — Biddeford, Maine, United States
• 205.372.01067 Boehringer Ingelheim Investigational Site — Columbia, Maryland, United States
• 205.372.01012 Boehringer Ingelheim Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.